1. Costagliola G, Peroni DG, Consolini R. Beyond infections: new warning signs for inborn errors of immunity in children. Front Pediatr 2022; 10: 855445.
2.
Rivière JG, Carot-Sans G, Piera-Jiménez J, et al. Development of an Expert-Based Scoring System for early identification of patients with inborn errors of immunity in primary care settings - the PIDCAP Project. J Clin Immunol 2024; 45: 26.
3.
Lankisch P, Schiffner J, Ghosh S, et al. The Duesseldorf warning signs for primary immunodeficiency: is it time to change the rules? J Clin Immunol 2015; 35: 273-9.
4.
Campbell E, Shaker MS, Williams KW. Clinical updates in inborn errors of immunity: a focus on the noninfectious clinical manifestations. Curr Opin Pediatr 2024; 36: 228-36.
5.
Bird JA, Sánchez-Borges M, Ansotegui IJ, et al. Skin as an immune organ and clinical applications of skin-based immunotherapy. World Allergy Organ J 2018; 11: 38.
6.
Taietti I, Catamerò F, Lodi L, et al. Inborn errors of immunity with atopic phenotypes in the allergy and immunology clinic: a practical review. Curr Opin Allergy Clin Immunol 2025; 25: 105-14.
7.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; Suppl 92: 44-7.
8.
Reynolds M, Gorelick J, Bruno M. Atopic dermatitis: a review of current diagnostic criteria and a proposed update to management. J Drugs Dermatol 2020; 19: 244-8.
9.
Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin 2017; 35: 317-26.
10.
Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract 2019; 7: 1763-70.
11.
Tsilifis C, Freeman AF, Gennery AR. STAT3 hyper-IgE syndrome – an update and unanswered questions. J Clin Immunol 2021; 41: 864-80.
12.
Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections – an autosomal dominant multisystem disorder. N Engl J Med 1999; 340: 692-702.
13.
Woellner C, Gertz EM, Schäffer AA, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol 2010; 125: 424-32.e8.
14.
Maecker HT, Rinfret A, D’Souza P, et al. Standardization of cytokine flow cytometry assays. BMC Immunol 2005; 6: 13.
15.
de Jager W, te Velthuis H, Prakken BJ, et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10: 133-9.
16.
Olsen I, Sollid LM. Pitfalls in determining the cytokine profile of human T cells. J Immunol Methods 2013; 390: 106-12.
17.
Mahnke YD, Brodie TM, Sallusto F, et al. The who’s who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol 2013; 43: 2797-809.
18.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European task force on Atopic Dermatitis. Dermatology 2013; 186: 29-31.
19.
Grimbacher B, Schäffer AA, Holland SM, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 1999; 65: 735-44.
20.
Mahnke YD, Beddall MH, Roederer M. OMIP-017: human CD4(+) helper T-cell subsets including follicular helper cells. Cytometry A 2013; 83: 439-40.
21.
Wingender G, Kronenberg M. OMIP-030: Characterization of human T cell subsets via surface markers. Cytometry A 2015; 87: 1067-9.
22.
Özçifci G, Arbağ SN, Kendir-Demirkol Y, Milner JD. Primary atopic disorders: expanding field of inborn errors of immunity. Turk J Immunol 2024; 12: 60-70.
23.
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-22.
24.
Martin G, Aldredge L, DiRuggiero D, et al. An overview of atopic dermatitis disease burden, pathogenesis, and the current treatment landscape: recommendations for appropriate utilization of systemic therapies. J Clin Aesthet Dermatol 2025; 18: 51-66.
25.
Yamamura Y, Nakashima C, Otsuka A. Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human. Front Med 2024; 11: 1342176.
26.
Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357: 1608-19.
27.
Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448: 1058-62.
28.
Chandesris MO, Melki I, Natividad A, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine 2012; 91: e1-19.
29.
Renner ED, Torgerson TR, Rylaarsdam S, et al. STAT3 mutation in the original patient with Job’s syndrome. N Engl J Med 2007; 357: 1667-8.
30.
Cossarizza A, Chang HD, Radbruch AD, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol 2017. 47: 1584-797.
31.
Schmitt V, Rink L, Uciechowski P. The Th17/Treg balance is disturbed during aging. Exp Gerontol 2013; 48: 1379-86.
32.
Dhalla F, Fox H, Davenport EE, et al. Chronic mucocutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility. Clin Exp Immunol 2016; 184: 216-27.
33.
Shen E, Wang M, Xie H, et al. Existence of Th22 in children and evaluation of IL-22 + CD4 + T, Th17, and other T cell effector subsets from healthy children compared to adults. BMC Immunol 2016; 17: 20.
34.
Pieren DKJ, Boer MC, de Wit J. The adaptive immune system in early life: the shift makes it count. Front Immunol 2022; 13: 1031924.
35.
Botafogo V, Pérez-Andres M, Jara-Acevedo M, et al. Age distribution of multiple functionally relevant subsets of CD4+ T cells in human blood using a standardized and validated 14-Color EuroFlow Immune Monitoring Tube. Front Immunol 2020; 11: 166.
36.
Harris TJ, Grosso JF, Yen HR, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179: 4313-7.
37.
Zhang Y, Siegel AM, Sun G, et al. Human TH9 differentiation is dependent on signal transducer and activator of transcription (STAT) 3 to restrain STAT1-mediated inhibition. J Allergy Clin Immunol 2019; 143: 1108-18.e4.
38.
Ma CS, Avery DT, Chan A, et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 2012; 119: 3997-4008.
39.
Boos AC, Hagl B, Schlesinger A, et al. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy 2014; 69: L943-53.
40.
de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008; 205: 1543-50.
41.
Becker KL, Gresnigt MS, Smeekens SP, et al. Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients. Clin Exp Allergy 2015; 45: 423-37.
42.
AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel; Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol 2024; 132: 274-312.
43.
Wollenberg A, Kinberger M, Arents B, et al. European Guideline (EuroGuiDerm) on atopic eczema: living update. J Eur Acad Dermatol Venereol 2025; 39: 1537-66.
44.
Lotfi N, Thome R, Rezaei N, et al. Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update. Front Immunol 2019; 10: 1265.